KADAR TSH DI MuLTIDRuG ReSISTAnCe TuBeRCuLoSIS TERKAIT ETIONAMID

Suparyatmo Suparyatmo, B. Rina A.S, Harsini Harsini, Musayadah Musayadah

Abstract


Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis and health problem and cause of death worldwide. MDR-TB occurs in patients who are inadequate and irregular in treatment. WHO strategy for MDR-TB is taking anti-tuberculosis (OAT) which has the effect of second-line heavier. Ethionamide one second-line OAT is administered orally and has a side effect of hypothyroidism. A cross-sectional descriptive study was conducted on 18 patients with MDR-TB from July 2012–March 2013. One patient has been excluded due to hypothyroidism. Increased TSH levels exceeded the cut-off occurred in 2 of 4 people after 1 month of treatment, 3 of 3 people after the 5th month of treatment, 1 of 4 people after 6 months of treatment and 1 of 3 people after month 9 treatment. Only 1 person who had increased levels of TSH>10 μIU/ mL. Conclusion: in patients with MDR-TB evaluation is required to determine the levels of TSH hypothyroidism.


Keywords


MDR-TB;ethionamid;TSH level

Full Text:

PDF


DOI: http://dx.doi.org/10.24293/ijcpml.v20i3.472

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.